PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 17, 2000Journal of Clinical Oncology2,312 citationsOpen Access

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

View Full Paper
HMHans von der MaaseSHSteen Werner HansenJRJ.T. Roberts

Key Points

  • Compare the efficacy, tolerability, and safety of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced or metastatic transitional cell carcinoma.
  • Multinational, multicenter, randomized phase III clinical trial.
  • Evaluated patients with locally advanced or metastatic transitional cell carcinoma receiving either gemcitabine plus cisplatin or standard MVAC chemotherapy.
  • Gemcitabine plus cisplatin demonstrated an overall survival outcome comparable to that of standard MVAC therapy.
  • Gemcitabine plus cisplatin provided a superior safety profile with significantly improved treatment tolerability relative to MVAC.

Abstract

GC provides a similar survival advantage to MVAC with a better safety profile and tolerability. This better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Maase et al. (2000) studied this question.

synapsesocial.com/papers/69d9845c5e5bcb4e3b836e80https://doi.org/10.1200/jco.2000.18.17.3068
Ask AI
Helpful
Bookmark
Share
View Full Paper